While it remains to be seen how the drug pricing provisions imposed by the IRA will affect the broader pharmaceutical industry, several pharmaceutical manufacturers and other industry stakeholders have challenged the law, including through lawsuits brought against the U.S. Department of Health and Human Services (HHS), the Secretary of HHS, CMS, and the CMS Administrator challenging the constitutionality and administrative implementation of the IRA’s drug price negotiation provisions.
All entries for: Atara Biotherapeutics
November 12, 2025
Atara Biotherapeutics
Neutral Outlook
Thousand Oaks, CA
201-500 employees
Since the May 12, 2025 “most favored nation” executive order, the Trump administration has continued to exert pressure on drug manufacturers toimplement “most favored nation” pricing and has suggested that it may impose significant tariffs on pharmaceuticals if such pricing is not implemented.
May 14, 2025
Atara Biotherapeutics
Layoffs
Thousand Oaks, CA
201-500 employees
Atara Biotherapeutics continues to shed its staff, announcing on Monday that it will downsize by approximately 30%, leaving only 23 employees behind who are “essential to executing on the Company’s strategic priorities,” according to an SEC filing.
Disease Area: Hematology, Immune Diseases, Multiple, Oncology
Drug Type: Biologic